Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Xspray Pharma in connection with share issue_
Mandate

Vinge has advised Xspray Pharma in connection with share issue

October 18, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of SEK 100 million.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson and Gabriel Chabo.

Related

Vinge advises Precise Biometrics in connection with rights issue
July 24, 2026

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

 Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026